Immunic Regains Nasdaq Minimum Bid Price Compliance, Resolving Delisting Threat
IMUX has more than doubled off its 52-week low of $0.506.
Summary
Immunic, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, removing a significant delisting risk that was highlighted in its recent 10-K filing.
Key Events · Corporate Governance and Compliance · IMUX
-
Regained Nasdaq Compliance
Immunic, Inc. received notification from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. This was achieved by maintaining a closing bid price of at least $1.00 per share for 20 consecutive business days, from February 27, 2026, to March 26, 2026.
-
Removes Delisting Threat
The compliance notification closes the matter, effectively removing the immediate threat of delisting from The Nasdaq Capital Market due to the minimum bid price deficiency.
-
Addresses Prior 10-K Concerns
This positive development directly addresses the 'ongoing Nasdaq compliance issues' and the potential need for a 'proposed reverse stock split' that were highlighted in the company's Annual Report on Form 10-K filed on February 26, 2026.
Analysis · IMUX · Life Sciences
This filing is important as Immunic, Inc. has officially regained compliance with Nasdaq's minimum bid price requirement. This resolves a significant compliance issue that was explicitly mentioned in the company's recent 10-K filing (2026-02-26) as a factor potentially requiring a reverse stock split. By maintaining a bid price above $1.00 for 20 consecutive business days, the company has removed an immediate delisting threat, providing stability regarding its exchange listing.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMUX was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.8M. The 52-week trading range was $0.51 to $1.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.